<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DD567D99-893B-43CA-B141-0C6A3D481748"><gtr:id>DD567D99-893B-43CA-B141-0C6A3D481748</gtr:id><gtr:name>School of Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Pathology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DD567D99-893B-43CA-B141-0C6A3D481748"><gtr:id>DD567D99-893B-43CA-B141-0C6A3D481748</gtr:id><gtr:name>School of Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D07F5C21-D59E-4175-8905-BF1DD37AAFF4"><gtr:id>D07F5C21-D59E-4175-8905-BF1DD37AAFF4</gtr:id><gtr:firstName>Thomas David Kay</gtr:firstName><gtr:surname>Brown</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/BE941673-99F3-43CA-A4BB-66DA04A4915C"><gtr:id>BE941673-99F3-43CA-A4BB-66DA04A4915C</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Digard</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801931"><gtr:id>D3D4BA02-8EFE-4898-A096-FD4C0B10D96D</gtr:id><gtr:title>Inhibition of influenza virus replication by macrolide antibiotics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801931</gtr:grantReference><gtr:abstractText>The threat of an influenza pandemic is constantly with us. The spread of bird flu across the world has heightened concerns about pandemic risk. This proposal is concerned with the development of drugs that will inhibit influenza virus growth and thereby prevent or reduce the severity of the associated illness. Our study will attempt to define the way in which these drugs work against flu. This information will be useful in improving our understanding of the influenza virus. It may also help us to develop better drugs in the future. The control of bird flu may be crucial in reducing the risk of a human pandemic; antiviral drugs may have a role in this. New flu drugs that can be used in humans will clearly be useful when a human pandemic next occurs.</gtr:abstractText><gtr:technicalSummary>The threat of a new influenza virus pandemic makes the development of new anti-influenza agents a priority. We have observed that certain macrolide antibiotics already licensed for use in poultry and swine inhibit the in vitro replication of influenza A virus strains at sub micromolar concentrations. Amongst these Aivlosin, (3-acetyl-4 -isovaleryl tylosin tartrate), is particularly promising given its low toxicity and rapid concentration in epithelia. Given the potential benefits to be gained from the identification of an antiviral activity for a licensed antimicrobial that is available in tonne quantities at relatively low cost, we think it is justified to pursue further studies aimed at characterising the effects of macrolides on influenza virus infection. We will investigate the mechanism of inhibition by Aivlosin and related compounds in vitro. The issues to be addressed will include the effects of the drugs on a range of key influenza strains in a variety of cell types, the putative antiviral effects of related compounds, the mechanism(s) of antiviral action, the potential for emergence of resistant mutants and finally their interactions with adamantanes. This proposal has potential implications for pandemic intervention strategies at both the animal and human levels.</gtr:technicalSummary><gtr:fund><gtr:end>2013-02-28</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>453752</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Physics</gtr:department><gtr:description>Macrolides and membrane structure</gtr:description><gtr:id>C51AC58C-D15F-4E7D-950E-AAF553C1491C</gtr:id><gtr:impact>The effects of the macrolides tylvalosin, clarithromycin and azithromycin on unilamellar structures were studied. Size reductions of giant unilamellar vesicles were observed in the presence of the drugs at uM concentrations. The rigidity of the membranes was reduced. Langmuir trough approaches were also used. Differences in membrane stabilisation by the drugs were observed. These changes may be relevant to the effects of macrolides on virus replication. Various signalling pathways have beeen considered in this context.</gtr:impact><gtr:partnerContribution>This collaboration has brought expertise in the analysis of lipid bilayer structure using biophysical methods. We are using this to study the effects of macrolides on membrane structure. This is relevant to mechanisms of their interactions with influenza virus replication.</gtr:partnerContribution><gtr:piContribution>We have provided expertise on macrolide structure and membrane biology.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Pharmacology</gtr:department><gtr:description>Phospholipase D and Influenza virus infection</gtr:description><gtr:id>29B2A8A6-9133-4CEA-B317-594DE2333B1F</gtr:id><gtr:impact>Inhibition of PLD2 inhibits influenza A virus (H3N2 and H1N1 strains including a 2009 pandemic strain) entry, genome trafficking and virus budding (investigations using siRNA knock down and the inhibitors provided by Vanderbilt)
Inhibition of PLD1 inhibits the entry of some influenza A virus strains.</gtr:impact><gtr:partnerContribution>Prof Alex Brown at Vanderbilt is a world renowned expert in PLD research and has provided significant intellectual input. He and Craig Lindsley have provided isoform selective inhibitors of phospholipase D to allow us to dissect out the roles of these proteins in influenza infection.</gtr:partnerContribution><gtr:piContribution>Intellectual input - we independently identified PLD2 as being an important protein during influenza A infection.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7282CBDD-3A4A-4DF3-912D-2DC27B845D51"><gtr:id>7282CBDD-3A4A-4DF3-912D-2DC27B845D51</gtr:id><gtr:title>Identification of a novel splice variant form of the influenza A virus M2 ion channel with an antigenically distinct ectodomain.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/16a3e92067207f4070e69b1efa752940"><gtr:id>16a3e92067207f4070e69b1efa752940</gtr:id><gtr:otherNames>Wise HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/36D9FC9D-8DE8-459E-ACF2-71F833AB3CAB"><gtr:id>36D9FC9D-8DE8-459E-ACF2-71F833AB3CAB</gtr:id><gtr:title>Role of the Rab11 pathway in negative-strand virus assembly.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/12166224984715583d7220bc66bd7d48"><gtr:id>12166224984715583d7220bc66bd7d48</gtr:id><gtr:otherNames>Bruce EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0F0D26F8-A217-42A2-8546-B1C868C21301"><gtr:id>0F0D26F8-A217-42A2-8546-B1C868C21301</gtr:id><gtr:title>Human cytomegalovirus inhibitor AL18 also possesses activity against influenza A and B viruses.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0c5d64eed95c3d26088351ba1dbab6a4"><gtr:id>0c5d64eed95c3d26088351ba1dbab6a4</gtr:id><gtr:otherNames>Muratore G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8B4C534A-BF5C-47C4-8A9C-ABC35D59F731"><gtr:id>8B4C534A-BF5C-47C4-8A9C-ABC35D59F731</gtr:id><gtr:title>Role of the Rab11 pathway in negative-strand virus assembly.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/12166224984715583d7220bc66bd7d48"><gtr:id>12166224984715583d7220bc66bd7d48</gtr:id><gtr:otherNames>Bruce EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AC80D1C2-5BD6-4821-96BF-D29A22CB6A4A"><gtr:id>AC80D1C2-5BD6-4821-96BF-D29A22CB6A4A</gtr:id><gtr:title>The Rab11 pathway is required for influenza A virus budding and filament formation.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/12166224984715583d7220bc66bd7d48"><gtr:id>12166224984715583d7220bc66bd7d48</gtr:id><gtr:otherNames>Bruce EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D39307A2-AB9B-4D40-80D1-D74922A2A992"><gtr:id>D39307A2-AB9B-4D40-80D1-D74922A2A992</gtr:id><gtr:title>Packaging signals in the 5'-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2affef47f36bd7c2d8cdcc9ec725f602"><gtr:id>2affef47f36bd7c2d8cdcc9ec725f602</gtr:id><gtr:otherNames>Giannecchini S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CAE0DC96-216D-4321-A105-D35A772EF3B7"><gtr:id>CAE0DC96-216D-4321-A105-D35A772EF3B7</gtr:id><gtr:title>Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0c5d64eed95c3d26088351ba1dbab6a4"><gtr:id>0c5d64eed95c3d26088351ba1dbab6a4</gtr:id><gtr:otherNames>Muratore G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801931</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>